Navigation Links
Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
Date:2/11/2013

EMERYVILLE, Calif., Feb. 11, 2013 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. 

Chest pain is the second leading cause of admittance to Emergency Departments in the US.  An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention.  The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.   Using a whole blood sample, the Omega-3 handheld system is designed to produce results in approximately 10 minutes at the site of first patient interaction, potentially reducing diagnosis of an MI by as much as an hour.  The cardiac test panel is the first developed for the Nanomix platform and extensions into other emergency medicine and infectious disease areas are planned to follow. 

About Nanomix Inc.

Nanomix's leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting.  Omega-3, the Nanomix mobile diagnostic platform, is designed to perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.  The compact size of the electronic and credit card sized disposable test cartridge can be configured to run a wide variety of tests from range of patient samples.

For more information, visit: http://www.nano.com

Contact:

David Ludvigson
dludvigson@nano.com
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA  94608
Phone:  1-510-428-5332


'/>"/>
SOURCE Nanomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
2. uniQure Initiates Phase I in Acute Intermittent Porphyria
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):